spacer
home > epc > spring 2009 > centralising ecgs
PUBLICATIONS
European Pharmaceutical Contractor

Centralising ECGs

Cardiac safety has become the number one reason for drug withdrawals and labelling changes during the past several years. This has resulted in greater regulatory scrutiny for all new compounds and greater concern among pharmaceutical companies in regard to the potential effect of their compounds on cardiac safety. One of the outcomes of this focus was the ICH E14 document, which provided guidance on the conduct of a dedicated ECG study which many term the ‘thorough QT (TQT) trial’ (1). These trials are generally conducted after proof of concept has been completed and employ digital and centralised ECGs as described in E14. However, although  almost all TQT trials are centralised, only approximately 20 to 25 per cent of all other clinical research (Phases I-IV) trials use centralised ECG analyses.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Dr Jeffrey S Litwin is a board certified Internist and Cardiologist. He left his cardiology practice in 1988 to serve as Director, Medical Affairs at Wyeth-Ayerst Laboratories. Jeffrey has been providing consultative support to the pharmaceutical industry for the design and conduct of cardiac safety trials and to the device industry for the design of ECG and Holter technologies for over 15 years. He is currently an Executive Vice President and the Chief Medical Officer for eResearchTechnology ERT), which he joined in July, 2000.

spacer
Jeffrey S Litwin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics Closes a $4.8 million USD (£3.7 million) Funding Round

Cambridge, UK, 10 June 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment. The funding will be used as working capital for the Company’s Cyto-Mine® Single Cell Analysis System, expansion of the UK facility and enable the doubling of personnel through the opening of a new US Sales Office and Demo Lab in California.
More info >>

White Papers

Contemporary Issues in Comparator Trial Supply

Clinigen CTS

As trial design and execution becomes ever-more complex, initiatives to adapt, increase efficiency and control costs without compromising quality become paramount. Here, Clinigen CTS covers the broad issues and summarises the responses our industry is making in this increasingly demanding landscape.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement